%PDF-1.4
%
101 0 obj
<>
endobj
98 0 obj
<>
endobj
174 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-05T16:08:22Z
2024-03-29T03:15:20-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T03:15:20-07:00
application/pdf
Heather
2003-121.march
uuid:de2f8ed3-1dd1-11b2-0a00-510827bd3700
uuid:de2f8ed6-1dd1-11b2-0a00-5b0000000000
endstream
endobj
87 0 obj
<>
endobj
88 0 obj
<>
endobj
102 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 71 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 73 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 75 0 R/Type/Page>>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 77 0 R/Type/Page>>
endobj
65 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 79 0 R/Type/Page>>
endobj
68 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 81 0 R/Type/Page>>
endobj
196 0 obj
[200 0 R]
endobj
197 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57.6 714.5293 Tm
[(18.)-500.1 (Lee SH, Soyoola E, Chanmugam P)110.7 (, et al. Selective expression of)]TJ
1.75 -1.25 Td
(mitogen-inducible cyclooxygenase in macrophages stimulated with)Tj
0 -1.25 TD
(lipopolysaccharide. J Biol Chem 1992;267:25934-8.)Tj
-1.75 -1.25 Td
[(19.)-500.1 (Geng )36.8 (Y)128.9 (, Blanco FJ, Cornelisson M, Lotz M. Regulation of)]TJ
1.75 -1.25 Td
(cyclooxygenase-2 expression in normal human articular )Tj
T*
(chondrocytes. J Immunol 1995;155:796-801.)Tj
-1.75 -1.25 Td
[(20.)-500.1 (Crof)17.7 (ford LJ, )17.7 (W)39.8 (ilder RL, Ristimaki )54.8 (AP)110.8 (, et al. Cyclooxygenase-1 and)]TJ
1.75 -1.25 Td
[(-2 expression in rheumatoid synovial tissues. Ef)17.7 (fects of interleukin-1)]TJ
T*
[(beta, phorbol ester)39.7 (, and corticosteroids. J Clin Invest 1)]TJ
0 Tc 0 Tw T*
(994;93:1095-101.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(21.)-500.1 (Kang R)54.8 (Y)128.9 (, Freire-Moar J, Sigal E, Chu CQ. Expression of )]TJ
1.75 -1.25 Td
(cyclooxygenase-2 in human and an animal model of rheumatoid)Tj
T*
[(arthritis. Br J Rheumatol 1996;35:71)36.8 (1-8.)]TJ
-1.75 -1.25 Td
[(22.)-500.1 (Ianaro )54.7 (A, Ialenti )54.7 (A, Maf)17.7 (fia P)110.7 (, et al. )54.7 (Anti-inflammatory activity of)]TJ
1.75 -1.25 Td
[(macrolide antibiotics. J Pharmacol Exp )17.7 (Ther 2000;292:156-63.)]TJ
-1.75 -1.25 Td
[(23.)-500.1 (Crof)17.7 (ford LJ, )17.7 (T)69.9 (an B, McCarthy CJ, Hla )17.7 (T)74 (. Involvement of nuclear)]TJ
1.75 -1.25 Td
(factor kappa B in the regulation of cyclooxygenase-2 expression by)Tj
T*
[(interleukin-1 in rheumatoid synoviocytes. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1997;40:226-36.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(24.)-500.1 (Aoki )36.8 (Y)128.9 (, Kao PN. Erythromycin inhibits transcriptional activation of)]TJ
1.75 -1.25 Td
[(NF-kappa B, but not NF)73.9 (A)110.8 (T)74 (, through calcineurin-independent)]TJ
-0.0298 Tw T*
[(signaling )-54.8 (in )-37.1 (T)-257.1 (cells. Antimicrob Agents )-54.8 (Chemother )]TJ
0 Tc 0 Tw T*
(1999;43:2678-84.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(25.)-500.1 (Laporte JD, Moore PE, )54.8 (Abraham JH, et al. Role of ERK MAP)]TJ
1.75 -1.25 Td
(kinases in responses of cultured human airway smooth muscle cells)Tj
T*
[(to IL-1 beta. )54.8 (Am J Physiol 1999;277:L943-51.)]TJ
-1.75 -1.25 Td
[(26.)-500.1 (Carter )54.8 (AB, Hunninghake GW)91.7 (. )54.8 (A)-220.1 (constitutive active MEK\320ERK)]TJ
1.75 -1.25 Td
(pathway negatively regulates NF-kappa B-dependent gene )Tj
T*
[(expression by modulating )17.7 (T)79.9 (A)110.8 (T)79.9 (A-binding protein phosphorylation. )]TJ
0 Tc T*
(J Biol Chem 2000;275:27858-64.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(27.)-500.1 (Guan Z, Buckman SY)128.8 (, Miller BW)91.7 (, Springer LD, Morrison )54.8 (AR.)]TJ
1.75 -1.25 Td
(Interleukin-1 beta-induced cyclooxygenase-2 expression requires)Tj
T*
(activation of both c-Jun NH2-terminal kinase and p38 MAPK signal)Tj
T*
(pathways in rat renal mesangial cells. J Biol Chem )Tj
0 Tc 0 Tw T*
(1998;273:28670-6.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(28.)-500.1 (Dean JL, Brook M, Clark )54.8 (AR, Saklatvala J. p38 mitogen-activated)]TJ
1.75 -1.25 Td
[(protein kinase regulates cyclooxygenase-2 mRNA)-220.2 (stability and )]TJ
T*
(transcription in lipopolysaccharide-treated human monocytes. J Biol)Tj
0 Tc T*
(Chem 1999;274:264-9.)Tj
-0.00011 Tc 31.25 47.5 Td
[(29.)-500.1 (Faour )17.7 (WH, He )36.8 (Y)128.9 (, He QW)91.7 (, et al. Prostaglandin E\(2\) regulates the)]TJ
1.75 -1.25 Td
[(level and stability of cyclooxygenase-2 mRNA)-220.2 (through activation of)]TJ
T*
(p38 mitogen-activated protein kinase in interleukin-1 beta-treated)Tj
T*
(human synovial fibroblasts. J Biol Chem 2001;276:31720-31.)Tj
-1.75 -1.25 Td
[(30.)-500.1 (Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark )54.8 (AR, Saklatvala J.)]TJ
1.75 -1.25 Td
[(A)-220.1 (p38 MAP)-238.2 (kinase inhibitor regulates stability of )]TJ
T*
(interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett)Tj
0 Tc 0 Tw T*
(1998;439:75-80.)Tj
0.0249 Tw -1.75 -1.25 Td
[(31.)-500 (Carter )54.8 (AB, Knudtson KL, Monick MM, Hunninghake GW)91.8 (. )17.7 (The p38)]TJ
-0.00011 Tc 1.75 -1.25 Td
(mitogen-activated protein kinase is required for NF-kappa )Tj
T*
[(B-dependent gene expression. )17.7 (The role of )17.7 (T)79.9 (A)110.8 (T)79.9 (A-binding protein. )]TJ
0 Tc T*
(J Biol Chem 1999;274:30858-63.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(32.)-500.1 (Lasa M, Mahtani KR, Finch )54.8 (A, Brewer G, Saklatvala J, Clark )54.8 (AR.)]TJ
1.75 -1.25 Td
[(Regulation of cyclooxygenase 2 mRNA)-220.2 (stability by the )]TJ
T*
(mitogen-activated protein kinase p38 signaling cascade. Mol Cell)Tj
0 Tc T*
(Biol 2000;20:4265-74.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(33.)-500.1 (Lasa M, Brook M, Saklatvala J, Clark )54.8 (AR. Dexamethasone )]TJ
1.75 -1.25 Td
[(destabilizes cyclooxygenase 2 mRNA)-220.2 (by inhibiting )]TJ
T*
(mitogen-activated protein kinase p38. Mol Cell Biol )Tj
0 Tc 0 Tw T*
(2001;21:771-80.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(34.)-500.1 (V)110.8 (ane JR. Inhibition of prostaglandin synthesis as a mechanism of)]TJ
1.75 -1.25 Td
(action for aspirin-like drugs. Nat New Biol 1971;231:232-5.)Tj
-1.75 -1.25 Td
[(35.)-500.1 (V)110.8 (ane JR, Botting RM. Mechanism of action of aspirin-like drugs.)]TJ
1.75 -1.25 Td
[(Semin )54.8 (Arthritis Rheum 1997;26 Suppl 1:2-10.)]TJ
-1.75 -1.25 Td
[(36.)-500.1 (Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate)]TJ
1.75 -1.25 Td
(and aspirin. Science 1994;265:956-9.)Tj
-1.75 -1.25 Td
[(37.)-500.1 (Nagai H, Shishido H, )36.8 (Y)99.8 (oneda R, )36.8 (Y)99.8 (amaguchi E, )17.7 (T)69.9 (amura )54.8 (A,)]TJ
1.75 -1.25 Td
[(Kurashima )54.8 (A. Long-term low-dose administration of erythromycin)]TJ
T*
[(to patients with dif)17.7 (fuse panbronchiolitis. Respiration 1991;58:145-9.)]TJ
-1.75 -1.25 Td
[(38.)-500.1 (Kudoh S, )54.8 (Azuma )54.8 (A, )36.8 (Y)99.8 (amamoto M, Izumi )17.7 (T)74 (,)-0.1 ( )54.8 (Ando M. Improvement)]TJ
1.75 -1.25 Td
[(of survival in patients with dif)17.7 (fuse panbronchiolitis treated with )]TJ
T*
[(low-dose erythromycin. )54.8 (Am J Respir Crit Care Med )]TJ
0 Tc 0 Tw T*
(1998;157:1829-32.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(39.)-500.1 (Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits)]TJ
1.75 -1.25 Td
[(neutrophil chemotaxis in bronchoalveoli of dif)17.7 (fuse panbronchiolitis.)]TJ
0 Tc T*
[(Chest 1994;106:1)36.9 (1)36.9 (16-23.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(40.)-500.1 (T)69.9 (akizawa H, Desaki M, Ohtoshi )17.7 (T)74 (, et al. Erythromycin modulates)]TJ
1.75 -1.25 Td
(IL-8 expression in normal and inflamed human bronchial epithelial)Tj
T*
[(cells. )54.8 (Am J Respir Crit Care Med 1997;156:266-71.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Fumimori, et al: Erythr)36.8 (omycin suppr)36.8 (esses COX-2)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(441)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
81 0 obj
<>stream
8;Z\6$$*p;#iu"-e9@?Nm%MU_Vf"8XdC+0<)'`7gOA[tp^'YHLSj0tKolJtQmU8qa
j8/\#Y"d\O>LQGFP%;I?:H`RgDcPJph&bFef4Sj_QJ/o
H]fl@'o'O>=Bl_O&QH\>\f&p(ra?Jmpp#Mlbu3UOL!CpsGMe?Ed?ELc#f1qiO$dZC
;NNR`l"O+q4plmt'dA[.i&jX:!;"Qq*H\.X$l2MHgLSq87*LmC$CQeL#4t4il8q
@*.%L[cSQnFEPnV/ultB@2eqAm<)Vi$L?\pkunQ(J)q*IeNr'p]J<(!da]'A*AfH)
YIQ?Nh^<`1'a2+U>/!G-M,dA_UUOicNb!)IT]Ihj5+r'uEK`*.$WG=qDc$p)>#h1-
G69,L/s_+7mZX=B\hNnGKe5`p;0SP&$A"_O9>LUsKmHEkZR!eb8r1gXXnWd)Z?HDh
X:8H^VRg3);eG'?G%9=+U,J`)/`6o[W(FqH@FC*f$"L%B245V;9joI3hb!!o]B8Z@XAa!.`M0fhHh&o7#`;;mq5mKL2.&Rq+r3&!@S\>RptPEG
d]7S.MPtV9?[Y]kG>n,.&9Sp2)]K_8)]KaRLU`@KS=Fi:.m$.3O^
endstream
endobj
85 0 obj
[/Indexed/DeviceRGB 255 84 0 R]
endobj
84 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
161 0 obj
<>
endobj
109 0 obj
<>
endobj
104 0 obj
<>
endobj
148 0 obj
<>
endobj
179 0 obj
<>
endobj
105 0 obj
<>
endobj
139 0 obj
<>stream
H{PSWrC-U+u"."*jM$@@@$yQ@TVu}+EElVgeFnzFv윙ߜ;9c;^&kwxBAcpfN0K,gcm-Vl-['~bE*-}moܱkt[g8ήj9_"d6y7 8>}P.ERzwrX"d/.o{/Kٷ7RG$'9F?bOߌ8AiM[SjeYE ȭATIyhFKܜͺI糗@dyj TkNk+k4ܭ8tۏs+jƍP6SWTc`KoaSti:
*dϕfjT=E@<$B̼$=IV,tU++<|